Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 6 | 2 | 8 |
| 1997 | 7 | 1 | 8 |
| 1998 | 11 | 3 | 14 |
| 1999 | 7 | 1 | 8 |
| 2000 | 9 | 4 | 13 |
| 2001 | 5 | 3 | 8 |
| 2002 | 8 | 7 | 15 |
| 2003 | 8 | 8 | 16 |
| 2004 | 6 | 6 | 12 |
| 2005 | 13 | 5 | 18 |
| 2006 | 13 | 4 | 17 |
| 2007 | 12 | 4 | 16 |
| 2008 | 23 | 8 | 31 |
| 2009 | 21 | 9 | 30 |
| 2010 | 20 | 12 | 32 |
| 2011 | 21 | 15 | 36 |
| 2012 | 20 | 5 | 25 |
| 2013 | 22 | 6 | 28 |
| 2014 | 34 | 13 | 47 |
| 2015 | 30 | 12 | 42 |
| 2016 | 13 | 22 | 35 |
| 2017 | 29 | 19 | 48 |
| 2018 | 41 | 17 | 58 |
| 2019 | 40 | 14 | 54 |
| 2020 | 30 | 23 | 53 |
| 2021 | 16 | 37 | 53 |
| 2022 | 9 | 45 | 54 |
| 2023 | 6 | 43 | 49 |
| 2024 | 27 | 25 | 52 |
| 2025 | 40 | 7 | 47 |
| 2026 | 17 | 4 | 21 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases. J Immunother Cancer. 2026 May 04; 14(5).
-
Malignant peripheral nerve sheath tumors: a report from Children's Oncology Group study ARST0332. J Natl Cancer Inst. 2026 May 01; 118(5):829-838.
-
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia. Hematol Oncol. 2026 May; 44(3):e70198.
-
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. Lancet Oncol. 2026 May; 27(5):592-603.
-
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026 Apr 30; 147(18):2041-2052.
-
POD24 is a novel determinant of prognosis in patients with Waldenstr?m macroglobulinemia. Blood Adv. 2026 Apr 14; 10(7):2322-2327.
-
Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort. J Natl Cancer Inst. 2026 Apr 01; 118(4):746-750.
-
The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells. Oncotarget. 2026 Mar 27; 17(1):78-89.
-
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results. Nat Cancer. 2026 Mar; 7(3):424-434.
-
Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332. Pediatr Blood Cancer. 2026 May; 73(5):e70228.